LL-37, MRGPRX2, and Rosacea: Where the Pathway Evidence Stands

Key Finding Human rosacea tissue consistently shows MRGPRX2 localized to lesional mast cells, and LL-37 triggers MRGPRX2-mediated mast cell degranulation in vitro — but direct, selective testing of this receptor in patients with rosacea has not been conducted.

Rosacea is a chronic inflammatory skin condition affecting an estimated 5–10% of adults worldwide, yet its pathophysiology remains incompletely understood. A critical narrative review published in Clinical, Cosmetic and Investigational Dermatology examines one of the more specific mechanistic hypotheses to emerge in recent years: that LL-37, an antimicrobial peptide, drives rosacea pathology through Mas-related G protein-coupled receptor X2 (MRGPRX2) on mast cells.

The review authors, Yin and Lu, conducted a thorough search of PubMed and the Web of Science Core Collection, supplemented by reference-list examination. What they found is a pathway with converging evidence across human tissue, cell-based, and animal studies — but with a gap at the level where it matters most for patients.

What the human tissue studies show

Multiple studies of rosacea-affected skin consistently demonstrate two things: changes in mast cell abundance and degranulation-associated staining in lesional tissue, and localization of MRGPRX2 to those same mast cells. This establishes that the receptor is present at the site of disease and that mast cells in rosacea lesions are activated.

This is the foundation of the hypothesis, and it rests on human tissue — not animal models — which is its strength. The presence of both the receptor and activated mast cells in the same lesion is consistent with MRGPRX2-mediated signaling playing a role in rosacea. It is not, however, proof of causation.

The functional evidence

In human mast cell lines and receptor-expression systems, LL-37 triggers MRGPRX2-mediated calcium signaling and degranulation — meaning the peptide can activate the receptor and produce a mast cell response. Pharmacological inhibition of MRGPRX2 can block these responses, providing further evidence that the receptor is the specific mediator.

These in vitro findings establish what the pathway can do mechanically. A mast cell sitting in a rosacea lesion, carrying MRGPRX2, encountering LL-37, would be expected to respond. That expectation is grounded in functional data.

The animal model gap

LL-37-induced mouse models of rosacea-like inflammation support contributions from mast cells and from MrgprB2, the murine orthologue of MRGPRX2. But the review notes an important pharmacological distinction: human MRGPRX2 and murine MrgprB2 have different ligand selectivity profiles. A finding in the mouse model may not translate directly to the human receptor.

The review also notes that other LL-37-responsive pathways and downstream regulatory processes could produce or modify similar mast-cell outcomes. MRGPRX2 is not the only route, and isolating its specific contribution requires experiments designed to exclude the others.

The missing human experiment

The review’s most useful observation may be what it identifies as absent: direct, selective functional testing of MRGPRX2 in patients with rosacea. Receptor-level functional findings come from cell lines; patient-level observations come from tissue staining — and these two levels of evidence arise from different study settings, different patients, and different measurement conditions.

What is needed, the authors argue, is a study design that connects lesional MRGPRX2 status with selective receptor perturbation and proximal mast-cell responses within the same rosacea study setting. If such a study found concordant signals, the MRGPRX2 hypothesis would gain substantial support. If it found partial, discordant, or subgroup-restricted responses, those would refine the receptor’s functional scope — still valuable information.

What this means for repair and skin research

The LL-37-MRGPRX2 pathway is one of the more tractable mechanistic hypotheses in rosacea research: it proposes a specific receptor, a specific ligand, a specific cell type, and a measurable output. It is not speculative in the way that broad “inflammation” hypotheses are. The building blocks are in place — human tissue localization, in vitro functional responses, and pharmacological inhibition data.

What is missing is not more mechanism studies, but human functional testing that connects the dots within the same patient. Until that experiment is done, MRGPRX2 involvement in rosacea remains a well-supported hypothesis rather than an established mechanism. The GHK-Cu reference protocol on ResearchProtocols covers another peptide with relevance to skin biology, though through a different mechanistic pathway entirely.